top of page
News
Stay up to date with the latest news from Fleet Bioprocessing by exploring our articles and blogs below:


Detector Labels and Bioconjugation in Lateral Flow Assays
(8-10 Minutes) Just as careful antibody selection is critical for Lateral Flow Assay (LFA) performance, the choice of detector label and its conjugation strategy directly influences assay sensitivity, specificity, reproducibility and scalability. Detector labels convert binding events into measurable signals and the way these labels are prepared and evaluated has a profound impact on how reliably an assay performs. Gold nanoparticles have become the most widely used detector
7 days ago


De-risking Early Lateral Flow Assay Development: Antibody Selection
(8-10 minutes) Antibody selection is one of the most influential decisions made during early Lateral Flow Assay (LFA) development. Whether antibodies are sourced commercially or developed as part of a broader LFA development service, the choices made at this stage directly affect assay sensitivity, specificity, reproducibility and long-term manufacturability. Applying a structured, risk based approach to antibody evaluation can significantly reduce technical and commercial ch
Feb 17


Choosing the Right Lateral Flow Assay Development Partner: Reducing Risk from Design to Scale.
(4-5 minutes) Lateral Flow Assays (LFAs) may look simple, but successful development is far from straightforward. Behind reliable, consistent performance lies careful control of multiple interacting variables that can otherwise introduce hidden risk. Too often, development challenges surface late, when changes are costly, timelines slip and verification efforts fail. The difference between a smooth path to market and repeated re-design frequently comes down to early technica
Feb 10


We are delighted to welcome Moya Mellors to Fleet Bioprocessing Ltd. as our new Lateral Flow Development Manager.
Moya joins us at an exciting stage for our Lateral Flow Development services. Moya brings over 15 years’ experience in Lateral Flow Assay development and a reputation for excellence in the field, with technical lab expertise, project management skills, and proven leadership. She has a strong track record of taking assays from development through to manufacturing, across multiple sectors, assay types and deployment settings. In her new role she will lead projects from feasibi
Feb 3


Fleet Bioprocessing Ltd. launch new service – Contract Development of Lateral Flow Devices!
We are excited to announce that Fleet Bioprocessing Ltd . are launching a new service: from today we will be offering contract development of lateral flow devices (LFDs) to our customers. LFDs form a cornerstone of modern diagnostics, providing a rapid means to detect diseases in a point-of-care (POC) format that can be used in people’s own homes or in primary care, with broader applications spanning clinical, veterinary, industrial and environmental settings. Traditionally
Jan 28


Happy New Year from Fleet Bioprocessing!
A frosty start to 2026 here at Pale Lane Farm - but we're all back at work and ready to discuss your New Year needs!
Jan 5
bottom of page
